Infection Risk During Targeted and Biologic Therapies in Rheumatoid Arthritis and Psoriatic Arthritis
An overview of the risk for infections during targeted and biologic therapies in rheumatoid arthritis and psoriatic arthritis.
Psoriatic Arthritis
Secukinumab Associated With Reduced Synovitis in Psoriatic Arthritis
The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.
Guselkumab Provides Sustained Improvements Through 1 Year in Patients With Active Psoriatic Arthritis
Study authors reported on the 1-year safety and efficacy of guselkumab treatment in patients with active psoriatic arthritis.
Weight Loss Linked to Reduced Disease Activity in Patients With Psoriatic Arthritis and Obesity
Researchers assessed the effects of weight loss on disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity.
Upadacitinib Effective in Reducing Pain in Patients With Psoriatic Arthritis With Inadequate Response to DMARDs
Study authors compared the effect of upadacitinib vs placebo and adalimumab on pain in patients with active psoriatic arthritis.
Response to Secukinumab Shows Variations Across Psoriatic Arthritis Clusters
Researchers compared the effect of secukinumab on the quality of life of patients with very early and established psoriatic arthritis.
Infliximab Shows Favorable Initial Efficacy, But Drug Survival Diminishes in Psoriasis, PsA
Survival and discontinuation rates of infliximab when treating psoriasis in real world conditions were analyzed.
Fibromyalgia in Psoriatic Arthritis Associated With Sleep Disturbances and Poor Quality of Life
Researchers evaluated the association between fibromyalgia in psoriatic arthritis and enthesopathy, sleep, fatigue, and quality of life.
Carotid Ultrasound May Be Beneficial for Cardiovascular Risk Stratification in Psoriatic Arthritis
Researchers evaluated the performance of carotid ultrasound in distinguishing between patients with psoriatic arthritis with and without coronary artery disease.
Golimumab Approved for Polyarticular JIA, Pediatric Psoriatic Arthritis
The FDA has approved Simponi Aria for the treatment of patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis.
-
Loading...
-
Loading...
Next post in Pediatric Rheumatology
